Tom 18, Nr 3 (2021)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2021-12-01
Wyświetlenia strony 4991
Wyświetlenia/pobrania artykułu 102
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Leczenie dyslipidemii w Polsce — interdyscyplinarne stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. IV Deklaracja Sopocka

Filip M. Szymański1, Agnieszka Mickiewicz2, Grzegorz Dzida3, Iwona Gorczyca-Głowacka45, Dariusz Kozłowski6, Krystyna Widecka7, Zbigniew Krasiński8, Adam Kobayashi910, Dagmara Hering11, Katarzyna Mizia-Stec12, Jarosław D. Kasprzak13, Tomasz Zubilewicz14, Krzysztof Narkiewicz11, Marek Koziński15, Anna E. Płatek16, Anna Ryś-Czaporowska17, Beata Chełstowska18, Stefan Grajek19, Marcin Wełnicki20, Artur Mamcarz20, Marcin Barylski21, Beata Wożakowska-Kapłon45, Miłosz J. Jaguszewski2, Marcin Gruchała2, Krzysztof J. Filipiak22
Choroby Serca i Naczyń 2021;18(3):95-120.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Wożakowska-Kapłon B, Filipiak KJ, Mamcarz A, et al. [Actual problems of dyslipidaemia treatment in Poland — 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy] [Article in Polish]. Kardiol Pol. 2014; 72(9): 847–853.
  2. Filipiak KJ, Cybulska B, Dudek D, et al. Aktualne problemy terapii dyslipidemii w Polsce — Deklaracja Sopocka. Stanowisko ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Choroby Serca i Naczyń. 2011; 8: 1–4.
  3. Szymański FM, Barylski M, Cybulska B, et al. Recommendation for the management of dyslipidemia in Poland — Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Cardiol J. 2018; 25(6): 655–665.
  4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
  5. Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017; 7(9): e016461.
  6. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, et al. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc. 2019; 8(24): e013225.
  7. Bruckert É, Gallo A. L’hypercholestérolémie familiale. Bull Acad Natle Méd. 2017; 201(7-9): 1323–1334.
  8. Mickiewicz A, Chmara M, Futema M, et al. Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland. Atherosclerosis. 2016; 249: 52–58.
  9. Rynkiewicz A, Cybulska B, Banach M, et al. Polish Lipid Expert Forum. [Management of familial heterozygous hypercholesterolaemia. Position paper of the Polish Lipid Expert Forum] [Article in Polish]. Kardiol Pol. 2013; 71(1): 107–111.
  10. Knowles JW, Rader D, Khoury M. Cascade screening for familial hypercholesterolemia and the use of genetic testing. JAMA. 2017; 318(4): 381.
  11. Sharifi M, Futema M, Nair D, et al. Polygenic hypercholesterolemia and cardiovascular disease risk. Curr Cardiol Rep. 2019; 21(6): 43.
  12. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013; 381(9874): 1293–1301.
  13. Futema M, Bourbon M, Williams M, et al. Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia. Atherosclerosis. 2018; 277: 457–463.
  14. Pająk A, Szafraniec K, Polak M, et al. WOBASZ Investigators. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Pol Arch Med Wewn. 2016; 126(9): 642–652.
  15. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016; 23(6): 636–648.
  16. Reiner Ž, De Backer G, Fras Z, et al. EUROASPIRE Investigators. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. Atherosclerosis. 2016; 246: 243–250.
  17. Bandosz P, O'Flaherty M, Drygas W, et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ. 2012; 344: d8136.
  18. Catapano AL, Graham I, De Backer G, et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37(39): 2999–3058.
  19. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011; 9(3): 258–270.
  20. Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015; 36(17): 1012–1022.
  21. Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members:, Authors/Task Force Members, Additional Contributor: Simone Binno (Italy), Document Reviewers:. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016; 23(11): NP1–NP96.
  22. Visseren FLJ, Mach F, Smulders YM, et al. ESC Scientific Document Group, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
  23. Garber AJ, Abrahamson M, Barzilay J, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. Endocr Pract. 2017; 23(2): 207–238.
  24. Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. J Am Coll Cardiol. 2017; 69(5): 471–482.
  25. Brunner FJ, Waldeyer C, Ojeda F, et al. Multinational Cardiovascular Risk Consortium. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. 2019; 394(10215): 2173–2183.
  26. Schoeneck M, Iggman D. The effects of foods on LDL cholesterol levels: a systematic review of the accumulated evidence from systematic reviews and meta-analyses of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021; 31(5): 1325–1338.
  27. Stefanick ML, Mackey S, Sheehan M, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998; 339(1): 12–20.
  28. Varady KA, Jones PJH. Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels? J Nutr. 2005; 135(8): 1829–1835.
  29. Szymanski FM, Semczuk-Kaczmarek K, Kuna P. "Health outcomes in COPD smokers using heated tobacco products: a 3‑year follow‑up: comment". Intern Emerg Med. 2021 [Epub ahead of print].
  30. deZeeuw D. Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Dialysis and Transplant Association Congress. Munich, Germany, June 27, 2010.
  31. Abe M, Maruyama N, Okada K, et al. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011; 18(11): 1018–1028.
  32. Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295(13): 1556–1565.
  33. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011; 365(22): 2078–2087.
  34. Mickiewicz A, Futema M, Ćwiklinska A, et al. Higher responsiveness to rosuvastatin in polygenic versus monogenic hypercholesterolaemia: a propensity score analysis. Life (Basel). 2020; 10(5).
  35. Wójcik C. Emerging lipid lowering agents targeting LDL cholesterol. Postgrad Med. 2020 [Epub ahead of print].
  36. Surma S, Romańczyk M, Filipiak KJ. Angiopoietin-like proteins inhibitors: new horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia. Cardiol J. 2021 [Epub ahead of print].
  37. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009; 301(22): 2331–2339.
  38. Wei WQ, Li X, Feng Q, et al. LPA variants are associated with residual cardiovascular risk in patients receiving statins. Circulation. 2018; 138(17): 1839–1849.
  39. Nicholls SJ, Bubb KJ. The riskier lipid: what is on the HORIZON for lipoprotein (a) and should there be Lp(a) screening for all? Curr Cardiol Rep. 2021; 23(8): 97.
  40. Cegla J, Neely RD, France M, et al. HEART UK Medical, Scientific and Research Committee. HEART UK consensus statement on lipoprotein(a): a call to action. Atherosclerosis. 2019; 291: 62–70.
  41. Rhainds D, Brodeur MR, Tardif JC. Lipoprotein (a): when to measure and how to treat? Curr Atheroscler Rep. 2021; 23(9): 51.
  42. Leebmann J, Roeseler E, Julius U, et al. Pro(a)LiFe Study Group*. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013; 128(24): 2567–2576.
  43. Moriarty PM, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. J Clin Lipidol. 2019; 13(6): 894–900.
  44. Mickiewicz A, Marlega J, Kuchta A, et al. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland. J Clin Apher. 2021; 36(3): 370–378.
  45. Szarek M, Bittner VA, Aylward P, et al. ODYSSEY OUTCOMES Investigators. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020; 41(44): 4245–4255.
  46. Banach M, Mikhailidis DP. Statin intolerance: some practical hints. Cardiol Clin. 2018; 36(2): 225–231.
  47. Alonso R, Cuevas A, Cafferata A. Diagnosis and management of statin intolerance. J Atheroscler Thromb. 2019; 26(3): 207–215.
  48. Ward NC, Watts GF, Eckel RH, et al. Statin toxicity. Circ Res. 2019; 124(2): 328–350.
  49. Diaconu CC, Iorga RA, Furtunescu F, et al. Statin intolerance: new data and further options for treatment. Curr Opin Cardiol. 2021; 36(4): 487–493.
  50. Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015; 132(13): 1224–1233.
  51. Navarese EP, Kolodziejczak M, Kereiakes DJ, et al. Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. Ann Intern Med. 2016; 164(9): 600–607.
  52. Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16): 1489–1499.
  53. Sabatine MS, Giugliano RP, Wiviott SD, et al. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16): 1500–1509.
  54. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014; 54: 273–293.
  55. Szymański F, Filipiak K, Wożakowska-Kapłon B, et al. Dyslipidemia aterogenna w codziennej praktyce — interdyscyplinarny konsensus polskich ekspertów. Folia Cardiol. 2017; 12(1): 33–49.
  56. Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovasc Diabetol. 2020; 19(1): 28.
  57. Sliż D, Filipiak KJ, Naruszewicz M, et al. Standards of statin usage in Poland in high-risk patients: 3ST-POL study results. Kardiol Pol. 2013; 71(3): 253–259.
  58. Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021; 325: 99–109.